Lupin Unit Settles Humana Antitrust Suit $30M

Lupin’s U.S. unit agreed to pay $30 million to settle Humana’s antitrust lawsuit alleging price‑fixing in the generics market.
The settlement does not admit wrongdoing; Lupin said it had already recorded the $30 million expense in its earnings.
The case stemmed from Humana’s broader suit against 37 pharma firms, including allegations of illegal reverse payments to delay Glumetza’s generic launch.
Last year Humana settled nearly $500 million with Sandoz, Sun Pharma and Taro, highlighting ongoing scrutiny of pharma pricing practices.